A retrospective database study of potential drug-drug interactions to novel anti-androgen agents among non-metastatic castration-resistant prostate cancer population
Latest Information Update: 02 Jun 2021
Price :
$35 *
At a glance
- Drugs Apalutamide (Primary) ; Darolutamide (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 Jun 2021 New trial record
- 20 May 2021 Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research